| Date | Title | Description |
| 30.03.2026 | WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year | SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year&quo... |
| 25.03.2026 | WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture | SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record... |
| 24.03.2026 | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
EBITDA rose 38.1%... |
| 23.03.2026 | WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO | Revenue increased by 46.7% YoY to RMB 5,944 million
Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024
Adjusted net profit increased by 69.9% YoY to RMB 1,559 m... |
| 22.03.2026 | World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target | SHANGHAI, March 22, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impa... |
| 13.03.2026 | WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation | SINGAPORE, March 13, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two indi... |
| 02.03.2026 | WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year | SHANGHAI, March 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 (&qu... |
| 12.02.2026 | WuXi Vaccines Receives Brazil's ANVISA GMP Certification | SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturin... |
| 03.02.2026 | WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vert... |
| 29.01.2026 | WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody | SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the dev... |
| 26.01.2026 | HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline | SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologic... |
| 26.01.2026 | WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline | SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanc... |
| 15.01.2026 | JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth | Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
Complex m... |
| 13.01.2026 | WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic | WUXI, China, Jan. 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility ... |
| 12.01.2026 | WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform de... |
| 19.12.2025 | WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security | SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship a... |
| 22.10.2025 | WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index | The only company from pharmaceutical industry selected for inclusion in the Index
Also included in HSI ESG Index and Hang Seng ESG 50 Index
Green CRDMO solution provider with outstanding sustainability performance
HONG KONG, Oct. 22, 2025 /... |
| 10.10.2025 | WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year | SHANGHAI, Oct. 10, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital Int... |
| 27.09.2025 | The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development | SINGAPORE, Sept. 27, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference bro... |
| 25.09.2025 | WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability | TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability.
The platform has achieved an average mAb titer exceeding 8.0 g/L w... |
| 23.09.2025 | WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year | SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index... |
| 17.09.2025 | Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK) | WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP... |
| 09.09.2025 | WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry | End-to-end Green CRDMO solutions to enable global clients for broader positive impact
Span from biologics research, development, manufacturing, and overall operations
Integration with lean management and digitalization for continuous excell... |
| 31.08.2025 | Asia markets close mixed as investors assess China’s RatingDog manufacturing data | Japanese, South Korean and Australian markets fell.
Hong Kong and Chinese stocks rise.
Asia-Pacific markets traded mixed Monday as investors assessed China’s RatingDog manufacturing data for August. The metric came in at 50.5, compared to a... |
| 28.08.2025 | WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi | Committed to net-zero across the value chain by 2050
Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- WuXi B... |
| 25.08.2025 | China Recap | Q2’s thrivers and strivers | China Recap is a weekly roundup tracking Chinese companies expanding abroad, covering market entries, funding rounds, product launches, and global partnerships.
China’s corporate globalization strategy is evolving fast. Industry giants are ... |
| 21.08.2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025
Thu, Aug 21, 2025 08:30 CET Report this content
Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its half-y... |
| 19.08.2025 | WuXi Biologics Reports Solid 2025 Interim Results | Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%
IFRS Gross profit margin expanded by 3.6% YoY to 42.7%
EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY
Adjusted EBITDA ... |
| 12.08.2025 | WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale | Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This ... |
| 11.08.2025 | WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules | WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.
WuXia293Stable platform maintains stable expression ... |
| 08.08.2025 | WuXi XDC Included in MSCI China All Share Index | SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today anno... |
| 07.08.2025 | WuXi Biologics Named to A List for CDP Supplier Engagement Assessment | Earns CDP's highest rating for supply chain engagement on climate
Adds to other CDP recognition—Water Security A List and leadership score on climate change
Drives sustainability through value chain decarbonization empowerment
SHANGHAI, Aug... |
| 05.08.2025 | WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity | WUXI, China, Aug. 5, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announc... |
| 29.07.2025 | WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication | Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.
Finished building will be one of the world's largest modular biologics... |
| 22.07.2025 | Value of Irish M&A halves in H1 but appetite for acquisitions remains | The volume of activity in the Irish mergers and acquisitions market increased slightly year-on-year in the first half of 2025, but the value of deals declined by 51 per cent from the same period last year.
The William Fry Half-Year M&A ... |
| 16.07.2025 | WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics | Best ESG rating tier of negligible-risk with a top 1% global ranking score
Industry and Regional ESG Top-Rated Company for five consecutive years
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, July 16, 2025 /PRNe... |
| 01.07.2025 | WuXi Biologics and WuXi XDC: Pioneering the Future of Biologics and Bioconjugates | In the ever-evolving landscape of biopharmaceuticals, innovation is the lifeblood that fuels progress. WuXi Biologics and WuXi XDC are at the forefront of this revolution, each carving a niche in the complex world of biologics and bioconjug... |
| 01.07.2025 | WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing | SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconj... |
| 30.06.2025 | WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL | The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL
It reduces viscosity by up to 90% while maintaining formulation stability and injectability
SHANGHAI, June 30... |
| 20.05.2025 | WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories | SHANGHAI, May 20, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announ... |
| 29.04.2025 | Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report | Contributing to United Nations Sustainable Development Goals
Enhancing transparency and effectiveness for corporate governance
Empowering employees and delivering positive impact to communities
Accelerating actions for tackling climate chan... |
| 22.04.2025 | WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year | Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals
Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future
SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("... |
| 19.04.2025 | WuXi Biologics: Pioneering the Future of Biopharmaceutical Manufacturing | In the bustling world of biopharmaceuticals, WuXi Biologics stands as a beacon of innovation. This Shanghai-based company has recently made headlines by clinching five prestigious awards at the 2025 Asia-Pacific Biopharma Excellence Awards.... |
| 18.04.2025 | WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site | - The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors
- Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20%
- As the company's largest op... |
| 14.04.2025 | WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards | SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pa... |
| 25.03.2025 | WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 | Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY
Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million
Added 151 new integrated projects, incl... |
| 24.03.2025 | WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024 | Revenue increased by 90.8% YoY to RMB 4,052 million
Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023
Net profit surged by 277.2% YoY to RMB 1,070 milli... |
| 21.03.2025 | WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year | Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6)
Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all
SHANGHAI, March 21, 20... |
| 13.03.2025 | WuXi Biologics and WuXi XDC: Pioneering the Future of Biologics and ADCs | In the fast-paced world of biotechnology, two names are making waves: WuXi Biologics and WuXi XDC. Both companies are at the forefront of innovation, pushing the boundaries of what's possible in drug development and manufacturing. Their rec... |
| 13.03.2025 | WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025 | SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in a... |
| 11.03.2025 | WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs | SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza... |
| 11.03.2025 | WuXi Biologics Included in S&P Global Sustainability Yearbook 2025 | Ranking in top 1% of S&P Global CSA Score
Inclusion in Global Yearbook for third consecutive year
Leader in Green CRDMO to drive innovation for a healthier future
SHANGHAI, March 11, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio&q... |
| 06.03.2025 | WuXi Biologics: Pioneering the Future of Biologics with EffiX™ and Unwavering Quality | In the fast-paced world of biotechnology, WuXi Biologics stands as a beacon of innovation. The company recently unveiled its EffiX™ Microbial Expression Platform, a game-changer in the production of recombinant proteins and plasmid DNA. Thi... |
| 04.03.2025 | WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production | - EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recom... |
| 27.02.2025 | WuXi Biologics Again Passed GMP Inspection by Japan PMDA | WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection... |
| 18.02.2025 | WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year | Ranked among the top 1% of more than 150,000 companies across 185 countries
Trusted by global partners for strong sustainability commitment
Recognized as a leader in Green CRDMO, driving innovation for a healthier future
SHANGHAI, Feb. 18, ... |
| 10.02.2025 | WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year | Ranked among the top 1% of companies assessed in the pharmaceutical industry
Recognized as a leader in Green CRDMO, driving innovation for a healthier future
Committed to creating long-term value for all stakeholders
SHANGHAI, Feb. 10, 2025... |
| 08.01.2025 | WuXi Biologics: Pioneering the Future of Biologics and Sustainability | In the bustling world of biotechnology, WuXi Biologics stands tall like a lighthouse guiding ships through foggy waters. This global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) is not just a player; it’s... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | CES 2025: A Showcase of Innovation Amidst Tensions | The Consumer Electronics Show (CES) 2025 has opened its doors in Las Vegas, showcasing a vibrant tapestry of technology and innovation. Over 1,300 Chinese companies have descended upon the event, a testament to their growing influence in th... |
| 07.01.2025 | Chinese tech firms label Pentagon list as a 'clear mistake'
Chinese firms display innovation and gadgets at CES 2025
China's WuXi Biologics sells Irish vaccine plant to Merck & Co
HDMI Forum launc... | Chinese tech giants, including SenseTime, Tencent and CATL, referred to their inclusion on a US Defense Department list of "Chinese military companies" as a "mistake" and a "false designation" on Tuesday.
They ... |
| 07.01.2025 | Chinese firms display innovation and gadgets at CES 2025
China's WuXi Biologics sells Irish vaccine plant to Merck & Co
Chinese tech firms label Pentagon list as a 'clear mistake'
HDMI Forum launc... | Over 1,300 Chinese companies attended the opening of the CES show in Las Vegas on Tuesday, the world's biggest consumer electronics show held annually.
They are showing the latest technology and gadgets such as the world's biggest LED TV, a... |
| 07.01.2025 | WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager | SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therape... |
| 02.01.2025 | WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year | Named for second consecutive year named to prestigious DJSI list
Leading green biologics solutions for a healthier future
SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Rese... |
| 14.12.2024 | The Green Revolution: Companies Leading the Charge in Sustainable Development | In a world grappling with climate change, two companies stand out for their commitment to sustainability: WuXi Biologics and Scandi Standard. Both have made significant strides in reducing their environmental impact, showcasing how business... |
| 12.12.2024 | WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection | Leading Green CRDMO Driven by Innovation for a Healthier Future
Offering End-to-end Green Biologics Solutions for the Entire Industry
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ... |
| 08.11.2024 | WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards | SHANGHAI and SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specia... |
| 28.10.2024 | WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development | SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield gluta... |
| 16.10.2024 | WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year | HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The... |
| 23.09.2024 | WuXi Biologics Included in Hang Seng ESG 50 Index | HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ES... |
| 11.09.2024 | The Rising Tide of Genomic Innovation: MGI's CycloneSEQ Technology and the Political Storm Surrounding Biotech | In the world of biotechnology, innovation is the lifeblood that fuels progress. MGI Tech Co., Ltd. has recently unveiled its latest advancements in nanopore sequencing technology, the CycloneSEQ-WT02 and CycloneSEQ-WY01. These products prom... |
| 07.09.2024 | Democrat to vote against bill restricting China's WuXi Biologics, BGI | Boards, Policy & RegulationHuman Rights
Democrat to vote against bill restricting China's WuXi Biologics, BGI
By Karen FreifeldSeptember 7, 20243:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Emai... |
| 21.08.2024 | WuXi XDC: A Surge in Growth and Ambition in the Bioconjugate Market | WuXi XDC Cayman Inc. is riding a wave of success. The company, a titan in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has unveiled impressive financial results for the first half of 2024. With a revenu... |
| 21.08.2024 | WuXi Biologics Reports Solid 2024 Interim Results | Revenue increased by 1.0% YoY to RMB 8,574.2 million
Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%
Added 61 new integrated projects, including 4 from late-phase and commerci... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
| 08.08.2024 | WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers | Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™
Collabor... |
| 01.08.2024 | WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics | WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities... |
| 24.07.2024 | Glanua secures strategic investment from Rabobank | Water infrastructure engineering group Glanua has secured funding from Rabobank as targets annual sales of €400m by 2028.
The level of funding offered by Rabobank has not been disclosed, but Glanua said it would enhance its capacity to scal... |
| 10.07.2024 | WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year | SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of t... |
| 30.04.2024 | WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment | The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.
The Company made remarkable progress in tackling climate change, achieving a 29% intensit... |
| 26.03.2024 | WuXi Biologics Reports Solid 2023 Annual Results | Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million
Gross Profit Rose by 1.5% to RMB6,827.9 Million
Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained
Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew ... |
| 25.03.2024 | WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones | Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022
Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022
Total number of integrated projects increased to 143
50 new integrated p... |
| 05.03.2024 | WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment | SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in... |
| 21.02.2024 | WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics | Named Top-Rated for fourth consecutive year
Committed to generating long-term value for all stakeholders
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Developmen... |
| 31.01.2024 | WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland | - First manufacturing run successful for MFG7 facility at the Ireland site
- Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors
DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics (&... |
| 31.01.2024 | WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development | SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clin... |
| 25.01.2024 | WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect | - WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse biop... |
| 24.01.2024 | WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs) | SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltr... |
| 17.01.2024 | WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ | SHANGHAI, Jan. 17, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, h... |
| 08.01.2024 | WuXi Biologics to Increase Manufacturing Capacity in Massachusetts | The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.
The site is expected to employ 250 people when fully operational.
WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("... |
| 13.12.2023 | WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023 | SINGAPORE, Dec. 13, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia... |
| 08.12.2023 | WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating | Ranked in top 1% of the over 100,000 companies evaluated
Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement
Seen as a trusted partner by global clients for its... |
| 06.12.2023 | WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader | SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at it... |
| 22.11.2023 | WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale | By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale
This end-to-end continuous bioprocess, which is in place fo... |
| 17.11.2023 | WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange | HONG KONG, Nov. 17, 2023 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization ("CRDMO") focused... |
| 08.11.2023 | WuXi Biologics Receives AAA MSCI ESG Rating | SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capi... |
| 20.10.2023 | WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards | SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract, Research, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the &... |
| 18.10.2023 | WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong | Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain in ... |
| 17.10.2023 | WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality | WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly improve productivity and quality, and r... |
